Vector, Per Se (e.g., Plasmid, Hybrid Plasmid, Cosmid, Viral Vector, Bacteriophage Vector, Etc.) Bacteriophage Vector, Etc.) Patents (Class 435/320.1)
-
Patent number: 9839677Abstract: The present invention provides compositions and methods for treating a myopathy. In certain embodiments, the invention provides compositions and methods for treating, improving muscle function, and prolonging survival in a subject with X-linked myotubular myopathy (XLMTM). The present invention provides a method comprising systemic administration of a composition that induces the increased expression of myotubularin in the muscle of a subject. The invention provides sustained regional and global increases in muscle function.Type: GrantFiled: July 26, 2016Date of Patent: December 12, 2017Assignees: Wake Forest University Health Sciences, Children's Medical Center Corporation, GenethonInventors: Martin K. Childers, Alan H. Beggs, Ana Maria Buj Bello
-
Patent number: 9834590Abstract: The present invention relates to a chimeric receptor capable of signaling both a primary and a co-stimulatory pathway, thus allowing activation of the co-stimulatory pathway without binding to the natural ligand. The cytoplasmic domain of the receptor contains a portion of the 4-1BB signaling domain. Embodiments of the invention relate to polynucleotides that encode the receptor, vectors and host cells encoding a chimeric receptor, particularly including T cells and natural killer (NK) cells and methods of use.Type: GrantFiled: October 1, 2015Date of Patent: December 5, 2017Assignee: St. Jude Children's Research Hospital, Inc.Inventors: Dario Campana, Chihaya Imai
-
Patent number: 9832957Abstract: The invention relates to the soybean variety designated 01058863. Provided by the invention are the seeds, plants and derivatives of the soybean variety 01058863. Also provided by the invention are tissue cultures of the soybean variety 01058863 and the plants regenerated therefrom. Still further provided by the invention are methods for producing soybean plants by crossing the soybean variety 01058863 with itself or another soybean variety and plants produced by such methods.Type: GrantFiled: June 2, 2016Date of Patent: December 5, 2017Assignee: Monsanto Technology LLCInventor: Jesse Gilsinger
-
Patent number: 9834777Abstract: The present invention provides novel DNA molecules and constructs, including their nucleotide sequences, useful for modulating gene expression in plants and plant cells. The invention also provides transgenic plants, plant cells, plant parts, seeds, and commodity products comprising the DNA molecules operably linked to heterologous transcribable polynucleotides, along with methods of their use.Type: GrantFiled: April 14, 2015Date of Patent: December 5, 2017Assignee: Monsanto Technology LLCInventor: Stanislaw Flasinski
-
Patent number: 9827278Abstract: The present invention concerns methods and compositions for the treatment of cancer and cancer cells using intravascular administration of a vaccinia virus. In some embodiments, methods and compositions involve a replicative vaccinia virus that encodes GM-CSF.Type: GrantFiled: October 6, 2015Date of Patent: November 28, 2017Assignee: SILLAJEN BIOTHERAPEUTICS, INC.Inventor: David Kirn
-
Patent number: 9828600Abstract: This disclosure provides methods and compositions for preparing and constructing cDNA libraries.Type: GrantFiled: September 22, 2014Date of Patent: November 28, 2017Assignee: University of MassachusettsInventors: Melissa J. Moore, Erin E. Heyer, Emiliano P. Ricci, Hakan Ozadam, Can Cenik, Xin Li
-
Patent number: 9827327Abstract: Embodiments of the invention are generally directed to compositions and methods of delivering one or more transgene to a target cell, such as a tumor cell, in a site-specific manner to achieve enhanced expression and to constructs and compositions useful in such applications. In certain aspects, expression from a therapeutic nucleic acid may be assessed prior to administration of a treatment or diagnostic procedure to or on a subject.Type: GrantFiled: February 23, 2012Date of Patent: November 28, 2017Assignee: The Board of Regents of the University of Texas SystemInventors: Renata Pasqualini, Wadih Arap, Juri Gelovani, Frank C. Marini, III, Amin Hajitou, Mian Alauddin, Martin Trepel
-
Patent number: 9823254Abstract: Provided herein, inter alia, are methods and compositions for removing a phosphopantethiene analog moiety from an ACP-phosphopantetheine conjugate thereby providing Apo-ACP proteins.Type: GrantFiled: March 13, 2015Date of Patent: November 21, 2017Assignee: The Regents of the University of CaliforniaInventors: Michael D. Burkart, Nicolas M. Kosa, Robert W. Haushalter
-
Patent number: 9822357Abstract: The invention refers to a library of bidirectional expression cassettes or expression vectors comprising a repertoire of bidirectional promoter sequences, each expression cassette comprising a promoter sequence operably linked to a first gene in one direction, and operably linked to an oppositely oriented second gene in the other direction which is different from the first gene, and bidirectional Pichia pastoris or CHO cells promoter sequences. The invention further refers to a method of screening or selecting a bidirectional promoter suitable for expressing at least two GOI in a host cell and a kit comprising a) an expression cassette consisting of the first and second genes and a stuffer sequence separating them, which stuffer sequence comprises a recognition site for a type IIS restriction enzyme at both ends; b) the type IIS restriction enzyme; c) and a repertoire of promoter, preferably a promoter library including bidirectional promoters.Type: GrantFiled: July 7, 2014Date of Patent: November 21, 2017Assignee: TECHNISCHE UNIVERSITAT GRAZInventors: Thomas Vogl, Thomas Kickenweiz, Lukas Sturmberger, Anton Glieder
-
Patent number: 9822351Abstract: The present invention relates to a hyaluronidase from S. koganeiensis, applications thereof and a method for the production thereof.Type: GrantFiled: June 13, 2014Date of Patent: November 21, 2017Assignee: FIDIA FARMACEUTICI S.P.A.Inventors: Luciano Messina, Luca Musumeci, Susanna Vaccaro
-
Patent number: 9816120Abstract: The invention provides compositions and methods for ligating single stranded nucleic acids wherein the ligation is based on fast, efficient, and low-sequence bias hybridization of an acceptor molecule with a donor molecule. In one embodiment, the structure of the donor molecule comprises a stem-loop intramolecular nucleotide base pairing (i.e., hairpin) and a 3?-overhang region such that the overhang is able to hybridize to nucleotides present in the 3? end of the acceptor molecule.Type: GrantFiled: January 9, 2014Date of Patent: November 14, 2017Assignee: THE PENN STATE RESEARCH FOUNDATIONInventors: Philip C. Bevilacqua, Sarah M. Assmann, Yiliang Ding, Chun Kit Kwok
-
Patent number: 9816991Abstract: The present invention relates, e.g., to a composition comprising peptides represented by SEQ ID NO:1-SEQ ID NO:28 and/or SEQ ID NO:41-SEQ ID NO:47, or active variants thereof, wherein the peptides or active variants can bind specifically to an antibody induced by a causative agent of Lyme disease (a pathogenic Borrelia), e.g. in a sample from a subject having Lyme disease. Compositions of the invention may comprise multiple peptides, from multiple proteins. Diagnostic kits comprising the peptides are described, as are diagnostic assays using the peptides.Type: GrantFiled: February 1, 2013Date of Patent: November 14, 2017Assignee: BIOPEPTIDES CORPORATIONInventors: Raymond J. Dattwyler, Paul M. Arnaboldi
-
Patent number: 9814198Abstract: A novel maize variety designated X05H205 and seed, plants and plant parts thereof are produced by crossing inbred maize varieties. Methods for producing a maize plant by crossing hybrid maize variety X05H205 with another maize plant are disclosed. Methods for producing a maize plant containing in its genetic material one or more traits introgressed into X05H205 through backcross conversion and/or transformation, and to the maize seed, plant and plant part produced thereby. This invention relates to the maize variety X05H205, the seed, the plant produced from the seed, and variants, mutants, and minor modifications of maize variety X05H205. This invention further relates to methods for producing maize varieties derived from maize variety X05H205.Type: GrantFiled: March 31, 2016Date of Patent: November 14, 2017Assignee: PIONEER HI-BRED INTERNATIONAL, INC.Inventors: Thomas Charles Barker, Joseph Kevin Gogerty, Wade Eugene Odland, Eric Scott Riedeman
-
Patent number: 9816098Abstract: Compositions and methods related to transgenic high oleic acid/ALS inhibitor-tolerant soybean plants are provided. Specifically, the present invention provides soybean plants having a DP-305423-1 event which imparts a high oleic acid phenotype and tolerance to at least one ALS-inhibiting herbicide. The soybean plant harboring the DP-305423-1 event comprises genomic/transgene junctions having at least the polynucleotide sequence of SEQ ID NO:8, 9, 14, 15, 20, 21, 83 or 84. The characterization of the genomic insertion site of the DP-305423-1 event provides for an enhanced breeding efficiency and enables the use of molecular markers to track the transgene insert in the breeding populations and progeny thereof. Various methods and compositions for the identification, detection, and use of the soybean DP-305423-1 events are provided.Type: GrantFiled: October 14, 2013Date of Patent: November 14, 2017Assignee: E I DU PONT DE NEMOURS AND COMPANYInventors: Anthony J. Kinney, Kevin L. Stecca, Knut Meyer, Kent Brink, Robert F. Cressman, Natalie N. Weber, Cathy Xiaoyan Zhong
-
Patent number: 9816134Abstract: Compositions and methods for amplifying selected polynucleotides, including DNA and RNA, particularly in multiplex amplification reactions using common primers amplification. Generally, methods of the invention employ multiple steps such as template-specific hybridization, a linear amplification, partial degradation of nucleic acid, and ligation. At the end of the process the sequences of selected polynucleotides are flanked by the common sequences which can be used for exponential amplification using common primers. In some aspects the polynucleotides are associated with a barcode and the presence of the barcode is detected to measure the amount of the polynucleotide.Type: GrantFiled: August 11, 2014Date of Patent: November 14, 2017Assignee: Affymetrix, Inc.Inventor: Eugeni A. Namsaraev
-
Patent number: 9809817Abstract: This disclosure relates to novel huntingtin targets. Novel oligonucleotides for the treatment of Huntington's disease are also provided.Type: GrantFiled: April 1, 2016Date of Patent: November 7, 2017Assignee: UNIVERSITY OF MASSACHUSETTSInventors: Anastasia Khvorova, Neil Aronin, Julia Alterman
-
Patent number: 9809861Abstract: A method of evaluating inhibitory effect on damp-dry malodor, containing the steps of: bringing microorganisms which produce damp-dry malodor-causing substances and a test substance into contact with each other in the presence of a sebaceous dirt component; detecting expression of at least one kind of gene selected from a fatty acid desaturase gene and a ? oxidation-related enzyme gene derived from the microorganisms; and thereby evaluating a damp-dry malodor inhibitory function of the test substance based on a change in expression amount of the at least one kind of gene.Type: GrantFiled: May 28, 2013Date of Patent: November 7, 2017Assignee: Kao CorporationInventors: Asako Mitani, Hiromi Kubota, Yu Niwano, Kohei Takeuchi, Atsushi Tanaka, Noriko Yamaguchi
-
Patent number: 9809801Abstract: Provided herein are genetically modified arenaviruses suitable as vaccines against mycobacterial infections. The invention also relates to pharmaceutical compositions and methods for the prevention and treatment of mycobacterial infections. Specifically, provided herein are pharmaceutical compositions, vaccines, and methods of preventing and treating infections in Mycobacterium tuberculosis.Type: GrantFiled: March 14, 2014Date of Patent: November 7, 2017Assignee: Université de GenèveInventors: Elodie Anne Françoise Belnoue, Stéphanie Gabrielle Darbre Abdelrahman, Arun Thomas Kamath, Paul Lambert, Claire-Anne Siegrist-Julliard, Daniel David Pinschewer
-
Patent number: 9803178Abstract: The present disclosure relates to engineered ketoreductase polypeptides for the preparation of hydroxyl substituted carbamate compounds, and polynucleotides, vectors, host cells, and methods of making and using the ketoreductase polypeptides.Type: GrantFiled: July 15, 2016Date of Patent: October 31, 2017Assignee: Codexis, Inc.Inventors: Fabien Louis Cabirol, Haibin Chen, Anupam Gohel, Steven J. Collier, Derek J. Smith, Birgit Kosjek, Jacob Janey
-
Patent number: 9803217Abstract: The present invention relates to viral vectors that are capable of delivering a heterologous gene to the retina and in particular delivering RLBP1 to RPE and Müller cells of the retina. The invention also relates nucleic acids useful for producing viral vectors, compositions comprising the viral vectors and uses of the compositions and viral vectors. The invention also relates to methods of delivering and/or expressing a heterologous gene to the retina, improving the rate of dark adaption in a subject and treating RLBP1-associated retinal dystrophy.Type: GrantFiled: October 13, 2015Date of Patent: October 31, 2017Assignee: NOVARTIS AGInventors: Vivian Choi, Chad Eric Bigelow, Thaddeus Peter Dryja, Seshidhar Reddy Police
-
Patent number: 9803191Abstract: The invention provides an expression and secretion system, and methods of using the same, for the expression and secretion of one fusion protein in prokaryotic cells and a second fusion protein in eukaryotic cells. Also provided herein are nucleic acid molecules, vectors and host cells comprising such vectors and nucleic acid molecules.Type: GrantFiled: July 3, 2013Date of Patent: October 31, 2017Assignee: Genentech, Inc.Inventors: Devin Tesar, Xiaocheng Chen, Mark Dennis, Isidro Hotzel
-
Patent number: 9801897Abstract: RNA encoding an immunogen is co-delivered to non-immune cells at the site of delivery and also to immune cells which infiltrate the site of delivery. The responses of these two cell types to the same delivered RNA lead to two different effects, which interact to produce a strong immune response against the immunogen. The non-immune cells translate the RNA and express the immunogen. Infiltrating immune cells respond to the RNA by expressing type I interferons and pro-inflammatory cytokines which produce a local adjuvant effect which acts on the immunogen-expressing non-immune cells to upregulate major histocompatibility complex expression, thereby increasing presentation of the translated protein to T cells. The effects on the immune and non-immune cells can be achieved by a single delivery of a single RNA e.g. by a single injection.Type: GrantFiled: July 6, 2011Date of Patent: October 31, 2017Assignee: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Andrew Geall, Katrin Ramsauer, Gillis Otten, Christian Mandl
-
Patent number: 9803216Abstract: Recombinant strains of avian paramyxovirus (APMV), such as Newcastle disease virus (NDV), are provided. Also provided are compositions comprising them, and methods of using them to lyse tumor cells and to treat cancer. In certain aspects, genetically-engineered viral strains that incorporate therapeutic transgenes are also provided. The recombinant viruses may be used in accordance with methods of providing enhanced oncolytic efficacy and delivering an oncolytic virus to tumors present in a patient. Also provided are methods for identifying a recombinant virus as an oncolytically-effective agent.Type: GrantFiled: September 7, 2012Date of Patent: October 31, 2017Assignee: University of MarylandInventors: Elankumaran Subbiah, Siba K. Samal
-
Patent number: 9795688Abstract: The invention relates to a nanostructured delivery system comprising at least one polymer and/or at least one lipid and at least one polymethine dye, wherein the at least one polymethine dye acting as a targeting unit brings about the targeted transport of the nanostructured delivery system into a target issue. The invention also relates to a pharmaceutical composition and the uses of the nanostructured delivery system for transporting said system and, optionally, a pharmaceutical active ingredient into the target tissue, as well for treating liver and/or kidney diseases.Type: GrantFiled: September 11, 2014Date of Patent: October 24, 2017Assignee: SMARTDYELIVERY GMBHInventors: Michael Bauer, Ulrich Schubert, Michael Gottschaldt, Anja Trager, Christian Pietsch, Falk Gonnert, Peter Recknagel, Adrian Press
-
Patent number: 9797018Abstract: Disclosed is a method for determining the presence of Mycobacterium avium complex nucleic acids in a biological sample. In particular, the mig gene of M. avium and the DT1 gene of M. intracellulare are detected, preferably following amplification. In addition, the method distinguishes between species of M. avium and M. intracellulare. Also described are oligonucleotides that can be used as primers to amplify target genes such as mig and DT1 genes and as probes as well as kits containing the oligonucleotide.Type: GrantFiled: November 14, 2011Date of Patent: October 24, 2017Assignee: Quest Diagnostics Investments IncorporatedInventors: Edgar Ong, Maurice Exner
-
Patent number: 9795667Abstract: This invention provides a method of attenuating porcine pseudorabies virus, which can effectively and reproducibly attenuate porcine pseudorabies virus. The attenuated strain of porcine pseudorabies virus by use of said method can provide effective immunization for pigs.Type: GrantFiled: July 6, 2015Date of Patent: October 24, 2017Assignee: PULIKE BIOLOGICAL ENGINEERING, INC.Inventors: Kegong Tian, Feifei Tan, Jinzhong Sun, Xuke Zhang
-
Patent number: 9790478Abstract: The present disclosure relates to polypeptides, including fusions thereof, nucleic acids, vectors, host cells, immunodiagnostic reagents, kits, and immunoassays for use detecting the presence of HCV antibodies. More specifically, the present invention describes specific NS3 antigens that can be used for the detection of anti-HCV antibodies.Type: GrantFiled: December 23, 2013Date of Patent: October 17, 2017Assignee: Abbott LaboratoriesInventors: A. Scott Muerhoff, Christopher Marohnic, Larry Birkenmeyer, John Prostko, M. Felisha Bogdan, Robin Gutierrez
-
Patent number: 9784665Abstract: The disclosure concerns a method for assessing muscular dystrophy-linked protein expression in muscle fibers using digital image analysis of tissue. The method relates to assessing disease severity in individuals with muscular dystrophy. Muscle tissue samples are obtained from patients submitted for evaluation and processed to produce tissue sections mounted on glass slides which have been stained for a muscular dystrophy-linked protein. Digital images of the stained tissue sections are generated and analyzed by applying an algorithm process implemented by a computer to the images. The algorithm process extracts the morphometric and staining features of the muscular dystrophy-linked protein staining in the tissue, and parameters relating to these features are used to score the disease status for each patient submitted for evaluation.Type: GrantFiled: December 29, 2015Date of Patent: October 10, 2017Assignee: Flagship Biosciences, Inc.Inventors: Anthony J. Milici, George David Young, Holger Lange, Joseph Krueger, Nathan T. Martin
-
Patent number: 9783819Abstract: Polynucleotides incorporated into nucleic acid constructs have been introduced into plants and were ectopically expressed. The encoded polypeptides of the invention have been shown to confer at least one regulatory activity and confer earlier flowering, longer floral organ retention, increased cold tolerance, greater tolerance to water deprivation, altered carbon-nitrogen balance sensing, increased low nitrogen tolerance, and/or increased tolerance to hyperosmotic stress as compared to a control plant.Type: GrantFiled: March 23, 2015Date of Patent: October 10, 2017Assignees: Mendel Biotechnology, Inc., Monsanto Technology LLCInventors: Jose Luis Riechmann, Oliver J. Ratcliffe, T. Lynne Reuber, Katherine Krolikowski, Jacqueline E. Heard, Omaira Pineda, Cai-Zhong Jiang, Robert A. Creelman, Roderick W. Kumimoto, Paul S. Chomet
-
Patent number: 9777066Abstract: The present inventor discovered stabilizing agents/stabilizing conditions for suppressing isomerization reactions of sc(Fv)2. It was also discovered that the above-mentioned isomerization reactions can be suppressed through use of freeze-dried formulations. As disclosed herein, by applying the discovered stabilizing agents/stabilizing conditions or the freeze-dried formulation, the isomerization reaction of an sc(Fv)2-type molecule from the bivalent scFv type to the single chain diabody type, and/or the isomerization reaction from a single chain diabody type to a bivalent scFv type can be suppressed in both directions or one direction.Type: GrantFiled: December 14, 2015Date of Patent: October 3, 2017Assignee: Chugai Seiyaku Kabushiki KaishaInventor: Tomoyuki Igawa
-
Patent number: 9778259Abstract: The present invention concerns an in vitro method for diagnosing invasive candidiasis (IC) in a subject which comprises detecting the presence of a Candida glycan and detecting the presence of antibody directed against a protein selected from the group consisting of fructose bisphosphate aldolase (Fba1), enolase 1 (Eno1), heat shock protein 90 (Hsp90), hyphal wall protein (Hwp1), and mannoprotein 65 (Mp65) in a blood, plasma or serum sample of the subject. The invention also relates to a method of determining a suitable treatment regimen for a patient and to a kit for implanting the methods described herein.Type: GrantFiled: March 18, 2013Date of Patent: October 3, 2017Assignees: Bio-Rad Innovations, Centre Hospitalier Universitaire De Lille, Universite Lille 2 Droit et SanteInventors: Sebastien Damiens, Chantal Fradin, Daniel Poulain, Boualem Sendid, Marc Charles Victor Tabouret
-
Patent number: 9777286Abstract: Provided are constructs and methods for expressing a transgene in plant cells and/or plant tissues using Zea mays metallothionein-like gene regulatory elements.Type: GrantFiled: October 2, 2014Date of Patent: October 3, 2017Assignee: Dow AgroSciences LLCInventors: Manju Gupta, Sandeep Kumar, Navin Elango, Karthik Narayna Muthuraman, Jeffrey Beringer, Huixia Wu, Nagesh Sardesai
-
Patent number: 9777285Abstract: The present invention is directed to promoter sequences and promoter control elements, polynucleotide constructs comprising the promoters and control elements, and methods of identifying the promoters, control elements, or fragments thereof. The invention further relates to the use of the present promoters or promoter control elements to modulate transcript levels in plants, and plants containing such promoters or promoter control elements.Type: GrantFiled: September 3, 2014Date of Patent: October 3, 2017Assignee: Ceres, Inc.Inventors: Richard Schneeberger, Emilio Margolles-Clark, Tatiana Tatarinova, Yiwen Fang, Nickolai Alexandrov, Leonard Medrano, Roger Pennell, Noah Theiss, Danielle Grizard, Shauna J. Davis, Dennis Robles, Michael Portereiko
-
Patent number: 9770463Abstract: RNA encoding an immunogen is co-delivered to non-immune cells at the site of delivery and also to immune cells which infiltrate the site of delivery. The responses of these two cell types to the same delivered RNA lead to two different effects, which interact to produce a strong immune response against the immunogen. The non-immune cells translate the RNA and express the immunogen. Infiltrating immune cells respond to the RNA by expressing type I interferons and pro-inflammatory cytokines which produce a local adjuvant effect which acts on the immunogen-expressing non-immune cells to upregulate major histocompatibility complex expression, thereby increasing presentation of the translated protein to T cells. The effects on the immune and non-immune cells can be achieved by a single delivery of a single RNA e.g. by a single injection.Type: GrantFiled: June 7, 2011Date of Patent: September 26, 2017Assignee: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Andrew Geall, Katrin Ramsauer, Gillis Otten, Christian Mandl
-
Patent number: 9765351Abstract: This invention relates to methods of controlling gene expression or gene suppression in eukaryotic cells. One aspect of this invention includes modifying the degree of silencing of a target gene by use of a modified suppression element. Another aspect includes providing a eukaryotic cell having a desired phenotype resulting from transcription in the eukaryotic cell of a modified suppression element. Also provided are transgenic eukaryotic cells, transgenic plant cells, plants, and seeds containing modified suppression elements, and useful derivatives of such transgenic plant cells, plants, or seeds, such as food or feed products.Type: GrantFiled: July 2, 2014Date of Patent: September 19, 2017Assignee: MONSANTO TECHNOLOGY LLCInventors: Joanne Fillatti, Jean C. Goley, Gregory R. Heck, Tichafa R. I. Munyikwa, Ty T. Vaughn, Toni Voelker
-
Patent number: 9765330Abstract: Allograft recognition and rejection of donor cells in a host is reduced by limiting or even abrogating expression of the donor cell's MHC-I peptides to avoid CD8+ T-cell recognition and by expression of inhibitory factors to avoid an NK cell mediated cytotoxic response.Type: GrantFiled: January 11, 2016Date of Patent: September 19, 2017Assignee: Nant Holdings IP, LLCInventors: Kayvan Niazi, Shahrooz Rabizadeh, Patrick Soon-Shiong
-
Patent number: 9765347Abstract: Provided is a transformant of S. pombe mutant which can produce and collect ?-glucosidase without requiring complicated separation steps, and a vector which is useful for transforming a yeast of the genus Schizosaccharomyces. The transformant of a S. pombe mutant of the present invention is a transformant of a Schizosaccharomyces pombe mutant which exhibits an increased Gsf activity and decreased or no pyruvyl transferase Pvg1 enzymatic activity, and is comprised of a structural gene sequence encoding a ?-glucosidase derived from a filamentous fungus, and a promoter sequence and a terminator sequence for expressing the structural gene in a chromosome or as an extrachromosomal gene. Further, the present invention relates to a cloning vector which is characterized by comprising a hsp9 gene promoter or an ihc1 gene promoter of a yeast of the genus Schizosaccharomyces, and is useful for transforming a yeast of the genus Schizosaccharomyces, an expression vector, a transformant, etc.Type: GrantFiled: February 20, 2015Date of Patent: September 19, 2017Assignee: Asahi Glass Company, LimitedInventors: Mayumi Kobayashi, Hideki Tohda, Shuichiro Kimura, Susumu Zen-In, Futoshi Hara
-
Patent number: 9765327Abstract: Described herein are methods and related compositions for inducing differentiation of human pluripotent stem cells (hPSCs) into hemogenic endothelium with pan-myeloid potential or restricted potential, by forced expression in the hPSCs of a combination of transcription factors as described herein.Type: GrantFiled: June 15, 2016Date of Patent: September 19, 2017Assignee: Wisconsin Alumni Research FoundationInventors: Igor Slukvin, Irina Elcheva
-
Patent number: 9765332Abstract: The present invention relates to oligonucleotides useful for inhibiting or reducing bacterial biofilms.Type: GrantFiled: January 29, 2015Date of Patent: September 19, 2017Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE DE RENNES 1Inventors: Brice Felden, Valerie Bordeau
-
Patent number: 9764044Abstract: The invention relates to methods of altering gene expression by homologous recombination in a multipotent adult progenitor cell (MAPC). In particular, methods of producing a recombinant MAPC, of correcting a genetic defect in a mammal, of providing a functional and/or therapeutic protein to a mammal, and of transforming a MAPC are provided. MAPCs containing an erogenous DNA as well as recombinant MAPCs and their differentiated progeny are also provided.Type: GrantFiled: May 21, 2010Date of Patent: September 19, 2017Assignee: ABT HOLDING COMPANYInventors: Catherine Verfaillie, Uma Lakshmipathy
-
Patent number: 9758563Abstract: An insulin analog comprises a B-chain polypeptide incorporating a chlorinated phenylalanine. The chlorinated phenylalanine may be located at position B24. The chlorinated phenylalanine may be para-monochloro-phenylalanine. The analog may be of a mammalian insulin, such as human insulin. A nucleic acid encodes such an insulin analog. The chlorinated insulin analogs retain significant activity. A method of treating a patient comprises administering a physiologically effective amount of the insulin analog or a physiologically acceptable salt thereof to a patient. Chlorine substitution-based stabilization of insulin may reduce fibrillation and thereby enhance the treatment of diabetes mellitus in regions of the developing world lacking refrigeration.Type: GrantFiled: June 22, 2015Date of Patent: September 12, 2017Assignee: Case Western Reserve UniversityInventor: Michael Weiss
-
Patent number: 9757120Abstract: The present disclosure is directed to a joining element elongate in a longitudinal direction including an inner core extending substantially in the longitudinal direction and an outer sleeve surrounding at least a portion of the inner core. The sleeve includes a lattice that defines at least one angle with respect to the longitudinal direction and the core is swellable against the sleeve along a direction perpendicular to the longitudinal direction to thereby increase the angle with respect to the longitudinal direction. The disclosure is further directed to a method of joining a first a second material including the joining element of the present disclosure.Type: GrantFiled: March 13, 2013Date of Patent: September 12, 2017Assignee: DePuy Synthes Products, Inc.Inventors: Joerg Mayer, Jochen Ganz, Beat Keller, Ralph Hertel
-
Patent number: 9745345Abstract: An anti-tumor polypeptide, having an amino acid sequence represented by FPGSDRF (SEQ ID NO: 15), X-FPGSDRF (SEQ ID NO: 16), FPGSDRF-Z (SEQ ID NO: 17), or X-FPGSDRF-Z (SEQ ID NO: 18) is disclosed. The various capital letters denote amino acids: F: phenylalanine; P: proline; G: glycine; D: aspartic acid; R: arginine; S is a phosphorylated serine residue, X and Z are an amino acid residue or an amino acid sequence, respectively, X is one selected from the group consisting of F, (R)9 (SEQ ID NO: 19), (R)9-F (SEQ ID NO: 20), 6-aminocaproic acid, 6-aminocaproic acid-F, 6-aminocaproic acid-(R)9 (SEQ ID NO: 21), and 6-aminocaproic acid-(R)9-F (SEQ ID NO: 22), Z is one selected from the group consisting of A, (G)n-RGD (SEQ ID NO: 23), and A-(G)n-RGD (SEQ ID NO: 24); and n is an integer greater than or equal to 0.Type: GrantFiled: November 16, 2015Date of Patent: August 29, 2017Assignee: NANJING MEDICAL UNIVERSITYInventors: Jianwei Zhou, Jin Xu, Xuan Li, Aiping Li
-
Patent number: 9745353Abstract: Anti-peptide antibodies (APAs) are extremely important tools for biomedical research. Many important techniques, such as immunoblots, ELISA immunoassays, immunocytochemistry, and protein microarrays are intrinsically linked to APA function and completely dependent on APA quality. Unfortunately, not all commercially-available APAs have good antigen binding characteristics; as a result, researchers are often unable to perform high quality protein analysis experiments. This disclosure describes a new method for the scalable production of polyclonal APAs using recombinant antigens. These recombinant peptide antigens have several advantages over traditional peptide antigens which improve the ease and speed of antibody production. The recombinant antigens can be scalably produced and purified much faster than traditional synthetic peptide-conjugates.Type: GrantFiled: November 29, 2011Date of Patent: August 29, 2017Assignee: Bioo Scientific CorporationInventors: Joseph Krebs, Paul Morrison, Jun Wang
-
Patent number: 9745638Abstract: The invention provides methods and compositions for rapid, sensitive, and highly specific nucleic acid-based (e.g., DNA based) detection of a BK virus in a sample. In general, the methods involve detecting a target nucleic acid having a target sequence of a conserved region of BK viral genomes. The invention also features compositions, including primers, probes, and kits, for use in the methods of the invention.Type: GrantFiled: April 29, 2014Date of Patent: August 29, 2017Assignee: Focus Diagnostics, Inc.Inventors: Fan Chen, Lilly I. Kong, Jules Chen, Mehrdad Jannatipour
-
Patent number: 9745590Abstract: Circular nucleic acid vectors that provide for persistently high levels of protein expression are provided. The circular vectors of the subject invention are characterized by being devoid of expression-silencing bacterial sequences, where in many embodiments the subject vectors include a unidirectional site-specific recombination product hybrid sequence in addition to an expression cassette. Also provided are methods of using the subject vectors for introduction of a nucleic acid, e.g., an expression cassette, into a target cell, as well as preparations for use in practicing such methods. The subject methods and compositions find use in a variety of different applications, including both research and therapeutic applications. Also provided is a highly efficient and readily scalable method for producing the vectors employed in the subject methods, as well as reagents and kits/systems for practicing the same.Type: GrantFiled: September 8, 2014Date of Patent: August 29, 2017Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Mark A. Kay, Zhi-Ying Chen
-
Patent number: 9737620Abstract: Improved DNA vaccine plasmids are disclosed that contain novel immunostimulatory RNA compositions. The improved plasmids eliminate all extraneous sequences, incorporate a novel antibiotic free short RNA based selectable marker, increase eukaryotic expression using a novel chimeric promoter, improve yield and stability during bacterial production, and improve immunostimulation. These vectors are utilized in immunization to elicit improved immune responses or therapy to induce type 1 interferon production.Type: GrantFiled: June 24, 2015Date of Patent: August 22, 2017Assignee: NATURE TECHNOLOGY CORPORATIONInventor: James A. Williams
-
Patent number: 9738908Abstract: The invention relates to engineered CRISPR/Cas9 systems for genomic modification and regulation of gene expression in mammalian cells. The specification describes the design and validation of polynucleotides encoding the Streptococcus pyogenes (S. pyogenes) Cas9 gene and protein and variants of that protein, where the nucleotide sequence has been optimized for expression in mammalian cells, and also modified by fused sequences that enhance various aspects of the CRISPR/Cas system. The specification also describes systems for RNA-guided genome engineering and gene regulation in mammalian cells, including human cells.Type: GrantFiled: March 17, 2014Date of Patent: August 22, 2017Assignee: System Biosciences, LLCInventor: Fangting Wu
-
Patent number: 9738900Abstract: The invention relates to transgenic plants with improved growth and nitrogen use efficiency expressing nitrate transporter gene, methods of making such plants and methods for improving growth and nitrogen use efficiency.Type: GrantFiled: October 4, 2016Date of Patent: August 22, 2017Assignees: Plant Bioscience Limited, Nanjing Agricultural UniversityInventors: Guohua Xu, Xiaorong Fan, Qirong Shen, Anthony Miller
-
Patent number: 9738890Abstract: The present invention relates to a method based on the use of restriction enzyme digestion and ligation via cleavage sites, thereby to prepare two or more standardized expression cassettes.Type: GrantFiled: March 27, 2013Date of Patent: August 22, 2017Assignee: DSM IP ASSETS B.V.Inventors: Johannes Andries Roubos, Herman Jan Pel, Bernard Meijrink